TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00657241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol CR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol CR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study: NCT01802658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NA Cl
Description: NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
Study: NCT02325336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCMA (bar-code-assisted medication administration)
Description: Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification.
Study: NCT01324349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veriset Hemostatic Patch
Description: Topical hemostat

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin Sealant (TachoSil®)
Description: Topical hemostat
Study: NCT04353011

Intervention type: OTHER
Intervention: questionnaire assesment
Description: questionnaire assesment
Study: NCT04225169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: The patient was taken to a quiet room and asked to lie on the bed. For the first 5 minutes, the researchers explained how the exercise is done with pictures and demonstrated it to the patient. The patient was asked to perform the exercise for 5 minutes under supervision by the researchers. If the patient performed DBE correctly, practice was discontinued. If not, the patient was asked to practice for another 5 minutes. If the patient still could not perform the exercise correctly at the end of this time, they were excluded from the sample. DBE was performed according to the Cleveland Clinic guideline as follows:
Study: NCT03896243

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine artery ligation (UAL)
Description: Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine artery ligation (UAL)
Description: Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)
Study: NCT02916615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High nitrate vegetables
Description: vegetables naturally high in nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low nitrate vegetables + nitrate
Description: pill containing KNO3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low nitrate vegetables
Description: vegetables naturally low in nitrate
Study: NCT00733122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
Study: NCT03334682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: Dispensation of spironolactone at each visit according to the arm description described above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
Study: NCT01555125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Description: After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
Study: NCT01289366

Intervention type: DEVICE
Intervention: Endocytoscopy
Description: Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
Study: NCT00774982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Release 6 mercaptopurine
Description: oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
Study: NCT03899558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humidified nasal high-flow device
Description: Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
Study: NCT02182505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®, high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® MDI
Study: NCT02117362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 mg/kg GR-MD-02
Description: 1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 mg/kg GR-MD-02
Description: 2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mg/kg GR-MD-02
Description: 4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8 mg/kg GR-MD-02
Description: 8 mg/mg GR-MD-02

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg ipilimumab on Days 1, 22, 43, and 65

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg ipilimumab on Days 1, 22, 43, and 65
Study: NCT00774982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 Mercaptopurine
Description: Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
Study: NCT02117362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg ipilimumab on Days 1, 22, 43, and 65

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg ipilimumab on Days 1, 22, 43, and 65
Study: NCT04152538

Intervention type: OTHER
Intervention: not intervention but investigation
Description: possible differences in quadriceps muscular activity
Study: NCT01461538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
Study: NCT03782922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training Program
Description: 10min of coordination and strength training (2-3x per week) during 2-6 weeks
Study: NCT02726022

Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: As per treating physician discretion and according to summary of product characteristics.

Intervention type: DRUG
Intervention: Ribavirin
Description: As per treating physician discretion and according to summary of product characteristics.
Study: NCT01371305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00011
Description: BG00011 will be administered at varying doses via subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
Study: NCT04659759

Intervention type: OTHER
Intervention: COVID-19 exposure
Description: COVID-19 exposure during pregnancy

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Receipt of any COVID-19 vaccine
Study: NCT02258113

Intervention type: DEVICE
Group type: OTHER
Intervention: Ocusweep
Description: A novel reaction-time based visual field device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ocusweep OcuRT
Description: Vision based choice reaction time test method
Study: NCT03399955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: Paromomycin (20 mg/kg/d) IM for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambisome
Description: AmBisome® (20 mg/kg total dose) IV over 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
Study: NCT02196389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal dilator Nasanita
Description: Nasal Dilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal dilator Nozovent
Study: NCT02258087

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LDR Brachytherapy
Description: In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR Brachytherapy
Description: In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
Study: NCT02196389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal dilator Breath Right

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal dilator Airmax
Study: NCT01501994

Intervention type: OTHER
Group type: OTHER
Intervention: GRUVE accelerometer (MUVE, inc.)
Description: Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GRUVE accelerometer (MUVE, inc.)
Description: Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.

Intervention type: OTHER
Group type: OTHER
Intervention: walking workstation
Description: The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
Study: NCT04413201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib followed by osimertinib or ICT
Study: NCT01501994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking workstation
Description: The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: exercise counseling
Description: After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise counseling
Description: After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
Study: NCT02326233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pen of SB5

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PFS of SB5
Study: NCT04892108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STARR (Stapled Trans Anal Rectal Resection)
Description: Patients randomly assigned to surgical intervention of STARR (Stapled Trans Anal Rectal Resection)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LVR (Laparoscopic Ventral Rectopexy)
Description: Patients randomly assigned to surgical intervention of LVR (Laparoscopic Ventral Rectopexy)
Study: NCT03337009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naloxone Navigator (NN)
Description: Patients prescribed chronic opioid therapy will be identified and recruited to enroll in the study. Patients randomized to receive the web-based animated video (Naloxone Navigator) will be sent a link to the video after enrollment. The web-based, animated video provides education on what is an opioid overdose, how to prevent it, how to recognize an overdose, and how to respond with naloxone. This video also encourages patients to pick up naloxone from a pharmacy under a standing order.
Study: NCT01304589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: 6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose) for 12 weeks - total treatment period is 18 weeks
Study: NCT01388114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing Antibody Probe System (e- Ab sensing)
Description: Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
Study: NCT00551200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPN-100
Description: Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUPHENYL®
Description: BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
Study: NCT00107536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01386749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team
Description: Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
Study: NCT00653081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy method called Supervised Exercises
Description: Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shockwave Therapy
Description: Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
Study: NCT04503824

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva samples
Description: Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva samples
Description: Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva samples
Description: Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva samples
Description: Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
Study: NCT03602859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)
Study: NCT03976063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Nifedipine
Description: Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
Study: NCT01747928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual-chamber syringe
Description: dual-chamber syringe for mock injection
Study: NCT00640575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone and lidocaine hydrochloride
Description: Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
Study: NCT02232581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alovudine - low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alovudine - medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alovudine - high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01869283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diadynamic currents
Study: NCT02098577

Intervention type: OTHER
Intervention: Crossover
Description: Crossover cycle

Intervention type: OTHER
Intervention: Stabilometric Platform
Description: This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
Study: NCT04252989

Intervention type: OTHER
Intervention: data collection
Description: * Demographic data: age, sex~* Ophthalmological history: refraction of parents, previous refractions~* Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~* Potential undesirable events (halos, photophobia...)